Argenx Se · EURONEXT:ARGX
Argenx — Q1 2026 Earnings Presentation
14 slides from Argenx's earnings presentation, May 7, 2026
Slide 1: Leading a new era of innovation in immunology
Leading a new era of innovation in immunology 1 Q 2 0 2 6 F I N AN C I AL R E S U LT S C AL L M AY 7 , 2 0 2 6
Slide 2: Forward Looking Statements
Forward Looking Statements This presentation has been prepared by argenx se (“argenx” or the “company”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or representation by the presenter or
Slide 3: Commitment To Our Transformation Mission
Commitment To Our Transformation Mission Disciplined Scaling Leadership in FcRn Continuous Pipeline of Innovation VISION 2030 50 K Patients on Treatment 10 Labeled Indications 5 New Molecules in Phase 3 3
Slide 4: Empasiprubart: Our Second Potential Medicine
Empasiprubart: Our Second Potential Medicine Foundational First-in-Class Pipeline in a Immune Target Potential Best-in-Class Product Opportunity Complement C2-Specific Empasiprubart Factor C2 Antibody IgG IgM Mannose sugar MMN CP LP Registrational Readout 4Q 2026 C4 C2 CIDP C3 Registrational Readout
Slide 5: Building our Presence in Rheumatology
Building our Presence in Rheumatology Autoimmune Myositis PM Redefining Biology 10K MSAs1 linked to disease severity in IMNM; IMNM skin rash and treatment response in DM 20K Redefining Treatment 70K Phase 2: Significant improvement TOTAL in muscle strength (TIS) DM 40K Redefining Patient Outcomes No
Slide 6: Transformative Potential Across Pipeline Programs
Transformative Potential Across Pipeline Programs Efgartigimod Empasiprubart Adimanebart ARGX-213 ARGX-121 First-in-class Potent C2 MuSK agonist FcRn: Sustained IgA Sweeping Fc Fragment sweeping antibody antibody IgG reduction Antibody 15+ 3+ 3+ 15+ 3+ Indications Indications Indications Potential i
Slide 7: Product Net Sales of $1.3 Billion in Q1
Product Net Sales of $1.3 Billion in Q1 Product Net Sales by Quarter Q1 2026 growth vs Q1 2025 1.286 1.298 $’m (in millions of $) Q1 2026 Q1 2025 Growth Growth % * 1.127 China US 1,107 681 426 62% RoW Japan 67 32 35 111% Japan 949 Rest of the World 112 57 55 99% US 790 China supply 12 20 (8) (41%) 7
Slide 8: Q1 2026 Financial Summary
Q1 2026 Financial Summary Three months ended March 31 (in million of $) 2026 2025 Delivering Margin Expansion Product net sales 1,298 790 Other operating income* 15 17 Operating profit of $394 Total operating income 1,313 807 million, +183% YoY Cost of sales (121) (81) Research and development expen
Slide 9: Raising the Standard of Care for Patients
Raising the Standard of Care for Patients Securing broad and Driving earlier-line use of Disciplined, scalable simple patient access VYVGART in MG and CIDP commercial execution Jai, VYVGART Patient 9
Slide 10: Strong Momentum Across MG and CIDP
Strong Momentum Across MG and CIDP NEW PATIENT STARTS PRESCRIBER EXPANSION Amongst ~5,000 Highest Achieved Prescribers in the US since launch 2X increase since CIDP launch EARLIER LINE USE PFS EXPANDING DEMAND 4/5 68% Prescribers in the US of PFS patients Prefer to start with VYVGART as new to VYVG
Slide 11: Sustaining MG Leadership
Sustaining MG Leadership U.S. Addressable “ I can carry a bag of MG Patients +25K potting soil from my car to the patio. I could (and wanted to!) work +7K in my flower beds for longer than I’d Growth in +11K Biologics Share of Market 60K been able to prior to treatment with Ocular VYVGART.” 17K Sero
Slide 12: Raising the Bar in CIDP
Raising the Bar in CIDP Early-line use 87.5% Clinical responses observed among treatment-naïve patients in ADHERE post hoc analysis Sustained functional benefit 96 wks Mean grip strength continued to improve up to 96 weeks in open-label extension Scott, CIDP Patient AAN Presentation: ADHERE Study po
Slide 13: Innovation Has No Value Unless It Provides Meaningful Benefit to Patients
Innovation Has No Value Unless It Provides Meaningful Benefit to Patients 13
Slide 14: Alternative Performance Measure Statement
Alternative Performance Measure Statement In this document, argenx's financial results are provided in accordance with IFRS® Accounting Standards (IFRS) and using a non-IFRS financial measure, cash, cash equivalents and current financial assets. This value should not be viewed as a substitute for th